Compare Stocks

Date Range: 

 BridgeBio PharmaMirati TherapeuticsUnited TherapeuticsUltragenyx PharmaceuticalArrowhead Pharmaceuticals
SymbolNASDAQ:BBIONASDAQ:MRTXNASDAQ:UTHRNASDAQ:RARENASDAQ:ARWR
Price Information
Current Price$48.03$144.00$195.42$114.53$66.38
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score2.01.61.71.71.5
Analysis Score4.53.33.54.43.4
Community Score2.52.92.23.32.5
Dividend Score0.00.00.00.00.0
Ownership Score2.51.71.70.01.7
Earnings & Valuation Score0.60.01.30.60.0
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$71.67$226.46$227.14$143.94$87.58
% Upside from Price Target49.21% upside57.26% upside16.23% upside25.68% upside31.94% upside
Trade Information
Market Cap$7.17 billion$7.39 billion$8.75 billion$7.73 billion$6.91 billion
Beta0.821.640.522.191.62
Average Volume949,774487,705368,110448,226787,167
Sales & Book Value
Annual Revenue$40.56 million$3.34 million$1.45 billion$103.71 million$87.99 million
Price / Sales176.772,213.036.0474.5078.52
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$3.83 per share$9.67 per share$63.36 per share$11.32 per share$4.51 per share
Price / Book12.5414.893.0810.1214.72
Profitability
Net Income$-260,590,000.00$-213,260,000.00$-104,500,000.00$-402,730,000.00$-84,550,000.00
EPS($2.48)($5.69)($2.39)($7.36)($0.84)
Trailing P/E RatioN/AN/A18.49N/AN/A
Forward P/E RatioN/AN/A16.86N/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/A33.25%-119.19%-96.09%
Return on Equity (ROE)-109.88%-60.01%15.48%-50.69%-17.37%
Return on Assets (ROA)-48.54%-54.21%11.31%-26.87%-15.19%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio2.19%N/A0.24%N/AN/A
Current Ratio9.85%8.84%7.22%4.33%7.92%
Quick Ratio9.85%8.84%6.88%4.26%7.92%
Ownership Information
Institutional Ownership Percentage95.53%94.92%90.09%N/A65.52%
Insider Ownership Percentage40.32%4.10%10.90%8.20%4.00%
Miscellaneous
Employees385199950893232
Shares Outstanding149.28 million51.33 million44.80 million67.46 million104.09 million
Next Earnings Date8/10/2021 (Estimated)8/5/2021 (Estimated)8/4/2021 (Estimated)7/29/2021 (Estimated)8/4/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
Arrowhead Pharmaceuticals (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call TranscriptArrowhead Pharmaceuticals' (ARWR) CEO Christopher Anzalone on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:29 PM
Brokers Set Expectations for Arrowhead Pharmaceuticals, Inc.s FY2022 Earnings (NASDAQ:ARWR)Brokers Set Expectations for Arrowhead Pharmaceuticals, Inc.'s FY2022 Earnings (NASDAQ:ARWR)
americanbankingnews.com - May 6 at 11:40 AM
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Releases  Earnings Results, Misses Expectations By $0.60 EPSArrowhead Pharmaceuticals (NASDAQ:ARWR) Releases Earnings Results, Misses Expectations By $0.60 EPS
americanbankingnews.com - May 4 at 11:46 PM
Arrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter ResultsArrowhead Pharmaceuticals Reports Fiscal 2021 Second Quarter Results
finance.yahoo.com - May 4 at 7:17 PM
Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy?Is Arrowhead Pharmaceuticals (ARWR) A Smart Long-Term Buy?
finance.yahoo.com - May 3 at 2:13 PM
Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position?Should You Retain Your Arrowhead Pharmaceuticals (ARWR) Position?
finance.yahoo.com - April 30 at 2:10 PM
ARWR: Raising target price to $84.00ARWR: Raising target price to $84.00
finance.yahoo.com - April 29 at 8:24 PM
Arrowheads ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver DiseaseArrowhead's ARO-AAT Treatment Associated With Improved Fibrosis In Patients With Alpha-1 Liver Disease
finance.yahoo.com - April 28 at 6:33 PM
Arrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver DiseaseArrowhead Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease
finance.yahoo.com - April 28 at 8:32 AM
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) a Suitable Stock for New Investors Now?Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) a Suitable Stock for New Investors Now?
stocksregister.com - April 24 at 9:03 AM
When would be the best time to Buy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock?When would be the best time to Buy Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock?
stocksregister.com - April 18 at 3:55 AM
Interesting ARWR Put And Call Options For December 17thInteresting ARWR Put And Call Options For December 17th
nasdaq.com - April 16 at 3:38 PM
Notable Two Hundred Day Moving Average Cross - ARWRNotable Two Hundred Day Moving Average Cross - ARWR
nasdaq.com - April 12 at 1:32 PM
Arrowhead Pharmaceuticals is Now Oversold (ARWR)Arrowhead Pharmaceuticals is Now Oversold (ARWR)
nasdaq.com - March 5 at 5:51 PM
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe HypertriglyceridemiaArrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia
finance.yahoo.com - March 1 at 9:39 AM
Accredited Virtual Event Preview- Corning, Cookware CovidAccredited Virtual Event Preview- Corning, Cookware Covid
finance.yahoo.com - February 26 at 2:19 PM
These Analysts Just Made A Substantial Downgrade To Their Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) EPS ForecastsThese Analysts Just Made A Substantial Downgrade To Their Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) EPS Forecasts
nasdaq.com - February 12 at 7:15 AM
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analysts Just Slashed This Years EstimatesArrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Analysts Just Slashed This Year's Estimates
finance.yahoo.com - February 12 at 7:15 AM
ARWR: Multiple Data Readouts in 2021…ARWR: Multiple Data Readouts in 2021…
finance.yahoo.com - February 9 at 6:39 PM
Arrowhead Pharmaceuticals, Inc (ARWR) Q1 2021 Earnings Call TranscriptArrowhead Pharmaceuticals, Inc (ARWR) Q1 2021 Earnings Call Transcript
finance.yahoo.com - February 5 at 10:30 PM
First Week of September 17th Options Trading For Arrowhead Pharmaceuticals (ARWR)First Week of September 17th Options Trading For Arrowhead Pharmaceuticals (ARWR)
nasdaq.com - January 19 at 5:03 PM
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter ResultsArrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
finance.yahoo.com - January 19 at 5:03 PM
ARWR Jan 2021 65.000 callARWR Jan 2021 65.000 call
uk.finance.yahoo.com - December 31 at 11:12 PM
ARWR Jan 2021 25.000 putARWR Jan 2021 25.000 put
uk.finance.yahoo.com - December 31 at 11:12 PM
ARWR Feb 2021 105.000 callARWR Feb 2021 105.000 call
uk.finance.yahoo.com - December 31 at 1:07 PM
DateCompanyBrokerageAction
5/7/2021BridgeBio PharmaThe Goldman Sachs GroupLower Price Target
4/11/2021BridgeBio PharmaSVB LeerinkReiterated Rating
3/23/2021BridgeBio PharmaJefferies Financial GroupReiterated Rating
3/20/2021BridgeBio PharmaMizuhoInitiated Coverage
2/22/2021BridgeBio PharmaJPMorgan Chase & Co.Initiated Coverage
1/11/2021BridgeBio PharmaHC WainwrightBoost Price Target
12/14/2020BridgeBio PharmaBTIG ResearchBoost Price Target
11/5/2020BridgeBio PharmaPiper SandlerBoost Price Target
10/6/2020BridgeBio PharmaBMO Capital MarketsBoost Price Target
6/25/2020BridgeBio PharmaBank of AmericaInitiated Coverage
3/8/2021Mirati TherapeuticsOppenheimerLower Price Target
12/16/2020Mirati TherapeuticsCredit Suisse GroupBoost Price Target
12/8/2020Mirati TherapeuticsEvercore ISIInitiated Coverage
12/8/2020Mirati TherapeuticsJMP SecuritiesInitiated Coverage
11/10/2020Mirati TherapeuticsGuggenheimDowngrade
10/29/2020Mirati TherapeuticsBarclaysBoost Price Target
10/8/2020Mirati TherapeuticsCSFBBoost Price Target
2/25/2021United TherapeuticsWedbushBoost Price Target
1/20/2021United TherapeuticsCowenBoost Price Target
1/20/2021United TherapeuticsLADENBURG THALM/SH SHBoost Price Target
5/6/2021Ultragenyx PharmaceuticalCitigroupUpgrade
5/6/2021Ultragenyx PharmaceuticalCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellUpgrade
5/5/2021Ultragenyx PharmaceuticalMorgan StanleyLower Price Target
3/1/2021Ultragenyx PharmaceuticalStifel NicolausInitiated Coverage
1/11/2021Ultragenyx PharmaceuticalRobert W. BairdBoost Price Target
10/29/2020Ultragenyx PharmaceuticalCanaccord GenuityBoost Price Target
10/28/2020Ultragenyx PharmaceuticalTruistBoost Price Target
2/8/2021Arrowhead PharmaceuticalsB. RileyBoost Price Target
2/5/2021Arrowhead PharmaceuticalsChardan CapitalBoost Price Target
12/15/2020Arrowhead PharmaceuticalsUBS GroupInitiated Coverage
11/24/2020Arrowhead PharmaceuticalsRoyal Bank of CanadaBoost Price Target
11/24/2020Arrowhead PharmaceuticalsCantor FitzgeraldBoost Price Target
11/19/2020Arrowhead PharmaceuticalsSmith Barney CitigroupInitiated Coverage
(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.